Journal
IMMUNOTHERAPY
Volume 11, Issue 1, Pages 45-59Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0090
Keywords
acne inversa; biologic drugs; biologics; biologic therapy; hidradenitis suppurativa; management; therapy; treatment
Categories
Ask authors/readers for more resources
Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatosis characterized by an occurrence of nodules, abscesses, sinus tracks and scarring. Its pathogenesis is multifactorial and still not fully understood, therefore, current systemic therapies still remain a serious challenge. Increased levels of several proinflammatory cytokines have been reported in patients suffering from HS, therefore biologics appear as a new approach to therapy for this condition. Adalimumab is the only one internationally registered agent and should be considered first after the conventional therapies appear insufficient. The efficacy and safety profile of some preparations, like infliximab and etanercept was confirmed so far in randomized trials, but there are some new biologics which are still being evaluated and require more rigorous examination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available